Posted BY: Teresa | NwoReport
The Biden administration has announced plans to allocate $1.4 billion in taxpayer funds to support the development of additional experimental COVID vaccines as part of its “Project NextGen” health initiative. This move comes shortly after a report from Infowars revealed that federal agencies were preparing for new COVID restrictions in September. The decision has raised concerns about the government’s prioritization of profit for pharmaceutical companies over the effectiveness of the vaccines.
The Department of Health and Human Services (HHS) explained that the funding would be directed toward various pharmaceutical companies, nonprofits, and nongovernmental organizations. The initiative aims to accelerate the development of vaccines and treatments for COVID variants. HHS Secretary Xavier Becerra emphasized that this investment is essential to address potential future variants of the virus, allowing the administration to respond proactively to emerging challenges.
Trending: Exploring Pfizer-BioNTech’s Innovative Nucleoside-Modified Messenger RNA (modRNA) Technology for COVID-19 Vaccines: Unveiling Insights from Pfizer Documents
The Project NextGen initiative includes substantial grants and contracts to support different aspects of vaccine development. Notable allocations include $1 billion to four partners for Phase IIb clinical trial studies, $326 million to Regeneron for a next-generation monoclonal antibody against COVID-19, $100 million to Global Health Investment Corp. (GHIC) to expand future response technologies, and $10 million to Johnson & Johnson Innovation (JLABS) for a BARDA-JLABS partnership competition.
These developments coincide with media coverage of a mild COVID Omicron subvariant known as EG.5 and the call for the reintroduction of certain COVID restrictions, including mask mandates. Infowars had previously reported on the Biden administration’s preparation for new COVID restrictions in September, which aligns with the announcement of additional funding for COVID-related initiatives. It’s worth noting that some critics argue that the administration’s focus on financing Big Pharma raises questions about the effectiveness of the vaccines and the motives behind such allocations. The ongoing financial struggles faced by pharmaceutical companies like BioNTech, Moderna, and Pfizer further complicate the narrative surrounding the government’s investment in COVID-related projects.
Ultimately, the debate continues between those who support the administration’s investment in vaccine development as a proactive response to potential variants and those who raise concerns about the effectiveness and motivations behind the funding decisions. The evolving situation emphasizes the complex intersection of public health, economic interests, and government policy during the ongoing pandemic.